Horizon Discovery (Horizon) today announced it has signed a commercial agreement with Belgian computational fragment based drug discovery biotech Silicos NV (Silicos) relating to its X-MAN™ technology.
Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalised’ medicine.
The agreement covers the testing of a number of Silicos lead compounds on human isogenic cell-lines comprising specific genotypes targeted by the compound series. The approach will enable Silicos to gather information relating to the selectivity and mode-of-action of their compounds using model in-vitro systems.
“Dr Darrin M Disley, Chairman of Horizon says “the proprietary multi-target virtual screening approach being taken by Silicos is an exciting development and should lead to the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases including cancer. Horizon believes that its patient-relevant disease models will allow the determination of key compound selectivity information on Silicos lead compounds. We hope that this, first agreement will be the beginning of a long and productive relationship with Silicos.”
The terms of the agreement were not disclosed.